{
    "Trade/Device Name(s)": [
        "BUHLMANN fCAL ELISA"
    ],
    "Submitter Information": "BUHLMANN Laboratories AG",
    "510(k) Number": "K181012",
    "Predicate Device Reference 510(k) Number(s)": [
        "K160447"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NXO"
    ],
    "Summary Letter Date": "April 16, 2018",
    "Summary Letter Received Date": "April 17, 2018",
    "Submission Date": "May 22, 2018",
    "Regulation Number(s)": [
        "21 CFR 866.5180"
    ],
    "Regulation Name(s)": [
        "Fecal calprotectin immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Calprotectin"
    ],
    "Specimen Type(s)": [
        "Stool"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "96-well microtiter plate",
        "Standard plate reader"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Colorimetric assay"
    ],
    "Methodologies": [
        "ELISA",
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for BUHLMANN fCAL ELISA quantitative stool calprotectin immunoassay for differentiation and diagnosis of IBD versus IBS",
    "Indications for Use Summary": "Quantitative measurement of fecal calprotectin in human stool to aid in diagnosis of inflammatory bowel disease (Crohn\u2019s disease and ulcerative colitis) and differentiation of IBD from irritable bowel syndrome, in conjunction with other laboratory and clinical findings.",
    "fda_folder": "Immunology"
}